Seattle Genetics to Present at Bank of America Merrill Lynch 2017 Healthcare Conference
May 09 2017 - 7:00AM
Business Wire
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that
management will present at the Bank of America Merrill Lynch 2017
Healthcare Conference on Tuesday, May 16 at 9:20 a.m. Pacific Time.
The presentation will be webcast live and available for replay from
Seattle Genetics’ website at www.seattlegenetics.com in the
Investors and News section.
About Seattle Genetics
Seattle Genetics is an innovative biotechnology company that
develops and commercializes novel antibody-based therapies for the
treatment of cancer. The company’s industry-leading antibody-drug
conjugate (ADC) technology harnesses the targeting ability of
antibodies to deliver cell-killing agents directly to cancer cells.
ADCETRIS® (brentuximab vedotin), the company’s lead product, in
collaboration with Takeda Pharmaceutical Company Limited, is the
first in a new class of ADCs commercially available globally in 67
countries for relapsed classical Hodgkin lymphoma (HL) and relapsed
systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics
is also advancing vadastuximab talirine (SGN-CD33A; 33A), an ADC in
a phase 3 trial for acute myeloid leukemia. Headquartered in
Bothell, Washington, Seattle Genetics has a robust pipeline of
innovative therapies for blood-related cancers and solid tumors
designed to address significant unmet medical needs and improve
treatment outcomes for patients. The company has collaborations for
its proprietary ADC technology with a number of companies including
AbbVie, Astellas, Bayer, Celldex, Genentech, GlaxoSmithKline and
Pfizer. More information can be found at
www.seattlegenetics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170509005440/en/
Seattle Genetics, Inc.InvestorsPeggy Pinkston,
425-527-4160ppinkston@seagen.comorMediaBrandi Robinson,
425-527-2910brobinson@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From May 2023 to May 2024